As an example, novel and more expensive glucose-lowering drugs such as GLP-1 RAs, DPP-4 inhibitors and SGLT2 inhibitors are less often prescribed in type 2 diabetes patients with statutory compared with patients with private health insurance [15]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.